Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 13/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 3/20 | 0.42 |
| ▸ | HTR1B | P28222 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16070203 | 0.94 | FGFR3 (0.69) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL16070236 | 0.86 | FGFR3 (0.58) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL16070358 | 0.86 | FGFR3 (0.47) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL16070208 | 0.85 | FGFR3 (0.64) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL16070256 | 0.85 | FGFR3 (0.57) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL16070508 | 0.85 | FGFR3 (0.57) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL16070227 | 0.84 | FGFR3 (0.60) | FGFR3KCNH2 | |
| SCHEMBL16070238 | 0.84 | FGFR3 (0.62) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL16070205 | 0.83 | FGFR3 (0.49) | FGFR3KCNH2FGFR1FGFR2FGFR4 | |
| SCHEMBL16069792 | 0.83 | PTK2 (0.44) | FGFR3KCNH2FGFR1FGFR2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701680-B2 | Pyrimidine and pyridine compounds and their usage | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-07-11 | — | — | US | disclosed |
| US-20160024021-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-01-28 | — | — | US | disclosed |
| WO-2014139465-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024021-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | FGFR3, FGFR1, FGFR4 | FGFR3 1/4885KCNH2 2621/4885FGFR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.